Summary & Overview
CPT 86703: HIV-1 and HIV-2 Antibody Immunoassay, Single Assay
CPT code 86703 represents a laboratory immunoassay for the detection of HIV‑1 and HIV‑2 antibodies in a single assay, a critical tool in the diagnosis and screening of human immunodeficiency virus (HIV) infection. This code is widely used in clinical laboratories across the United States and is central to public health efforts aimed at early identification and management of HIV. The procedure is performed using multiple step methods, ensuring both qualitative and semiquantitative results that inform clinical decision-making.
Major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, provide coverage for this service, reflecting its importance in routine and specialized care. Readers will gain insight into payer coverage, relevant clinical contexts, and associated coding benchmarks. The publication also addresses policy updates, common billing modifiers, and related laboratory codes, offering a comprehensive overview for stakeholders involved in laboratory operations, billing, and compliance.
Key topics include the clinical significance of HIV testing, payer landscape, and coding nuances. The summary provides a foundation for understanding how 86703 fits into broader HIV testing protocols and laboratory billing practices, supporting informed decision-making for healthcare organizations and professionals.
CPT Code Overview
CPT code 86703 is used to report qualitative or semiquantitative immunoassays performed by multiple step methods for the detection of HIV‑1 and HIV‑2 antibodies in a single assay. This procedure falls under Pathology and Laboratory Procedures – Immunology Procedures and is typically performed in a laboratory setting, such as a facility-based laboratory. The test is essential for identifying HIV infection status and is a cornerstone in both diagnostic and screening protocols for HIV.
Clinical & Coding Specifications
Clinical Context
A patient presents to a healthcare provider for evaluation of possible human immunodeficiency virus (HIV) infection. The provider orders laboratory testing to detect antibodies to both HIV-1 and HIV-2 using a single assay. The specimen is collected and sent to a clinical medical laboratory, where a qualitative or semiquantitative immunoassay is performed using multiple step methods. The results assist in diagnosing HIV infection, screening for HIV status, or evaluating inconclusive prior laboratory findings. This workflow is typical in settings such as routine screening, evaluation of exposure, or confirmation of HIV status in asymptomatic or symptomatic individuals.
Coding Specifications
-
Modifier
59: Distinct Procedural Service. Used when the immunoassay is performed separately from other procedures, indicating it is not bundled with other laboratory tests. -
Modifier
91: Repeat Clinical Diagnostic Laboratory Test. Used when the same immunoassay is performed more than once on the same patient on the same day, typically to confirm results or monitor changes.
| Provider Taxonomy Code | Specialty Description |
|---|---|
291U00000X | Clinical Medical Laboratory |
207Q00000X | Family Medicine Physician |
207R00000X | Internal Medicine Physician |
Related Diagnoses
-
Z21– Asymptomatic human immunodeficiency virus [HIV] infection status- Indicates a patient has HIV infection but is not showing symptoms. Relevant for routine monitoring or screening.
-
B20– Human immunodeficiency virus [HIV] disease- Used when a patient has symptomatic HIV disease. Testing helps confirm diagnosis or monitor disease progression.
-
R75– Inconclusive laboratory evidence of human immunodeficiency virus [HIV]- Applied when previous HIV tests have yielded inconclusive results, necessitating repeat or confirmatory testing.
-
Z11.4– Encounter for screening for human immunodeficiency virus [HIV]- Used for patients undergoing routine HIV screening, such as in preventive care or public health programs.
-
Z20.6– Contact with and (suspected) exposure to human immunodeficiency virus [HIV]- Indicates a patient has been exposed or is suspected to have been exposed to HIV, prompting testing to determine infection status.
Related CPT Codes
-
86701– Antibody; HIV‑1- Used for testing HIV-1 antibodies only. May be ordered separately if only HIV-1 is suspected.
-
86702– Antibody; HIV‑2- Used for testing HIV-2 antibodies only. May be ordered separately if only HIV-2 is suspected.
-
86689– Qualitative or semiquantitative immunoassays performed by multiple step methods; HTLV or HIV antibody, confirmatory test (for example, Western Blot)- Used as a confirmatory test following initial HIV screening, often performed if the result of
86703is positive or inconclusive.
- Used as a confirmatory test following initial HIV screening, often performed if the result of
-
87390– Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semiquantitative, multiple‑step method; HIV‑1- Used for detecting HIV-1 antigen, which may be ordered alongside or as an alternative to antibody testing.
-
87391– Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semiquantitative, multiple‑step method; HIV‑2- Used for detecting HIV-2 antigen, which may be ordered alongside or as an alternative to antibody testing.
Codes 86701, 86702, 87390, and 87391 are commonly used as alternatives or in conjunction with 86703 depending on clinical suspicion and testing protocols. Code 86689 is typically used for confirmatory purposes after initial screening.
National Reimbursement Benchmarks
National mean rates for CPT code 86703 among commercial payers show that Cigna has the highest average reimbursement at $16.59, while UnitedHealth Group is lowest at $11.74. The BUCA average is $13.24, which is higher than UnitedHealth Group but lower than Cigna. Medicare rates are not available in the input for comparison.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. Blue Cross Blue Shield has the tightest range at $5.00, indicating less variability in rates, while Cigna exhibits the widest spread at $11.00, reflecting greater variability in reimbursement. UnitedHealth Group also shows a wide range of $7.00, while Aetna and BUCA are moderate at $5.56 and $6.30, respectively.
The table and chart below present the full breakdown of national benchmarks for CPT code 86703 by payer, including mean rates and percentile values.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.